China’s healthcare sector rose 0.9% in late June while the Hang Seng Index fell 7.4%. The gain followed Beijing’s approval of a five-year plan that treats health as a national priority.
Policy tailwinds offset weak sentiment
The State Council approved the National Health 15th Five-Year Plan (2026-30) on June 29. The document sets out a “whole-lifecycle” health service system and closer ties between medical care, insurance, and disease control. It also calls for expanding the health industry. Analysts at UOB Kay Hian said the plan could steady investor expectations after months of volatility.
Reimbursement reforms soon followed. The National Healthcare Security Administration reviewed 557 new drugs for the 2026 National Reimbursement Drug List. Another 54 drugs were added to the Commercial Health Insurance Innovative Drug List. A new pre-submission consultation process and eight-year price protection terms were introduced to address concerns about unpredictable returns on research investment.
Related: Label tech market set to grow
Weight-loss treatments are expected to grow. New oral and multi-target therapies should reach the Chinese market within 12 to 18 months. This expansion will broaden the patient base beyond current injectable options.
Device makers and digital health pivot to scale
Medical device manufacturers are growing faster than anticipated. Domestic surgical robotics firms reported first-half 2026 orders that already exceeded full-year 2025 levels in some areas. The increase stems from policy support and expansion into overseas markets, where Chinese systems are gaining ground due to lower costs and customization.
Digital health platforms are moving beyond drug sales. They now offer full-cycle disease management, shifting from one-time prescriptions to ongoing monitoring for chronic conditions like diabetes. New partnerships between platforms and multinational drugmakers are extending services from prescription fulfilment into ongoing chronic-disease monitoring and treatment support.
Related: Taiwan Sees Rise in Neuroendoscopy Procedures
Investor sentiment weakened during the second quarter. The gap between policy support and market performance led to share buybacks. Fifty-one Hong Kong-listed healthcare companies spent $879.8 million repurchasing shares, over five times the first-quarter amount. The move suggests insiders see the pullback as a valuation issue rather than a fundamental problem.
Overall, the sector’s outlook remains rated MARKET WEIGHT, with the greatest opportunity seen amongst drug innovators with strong pipelines and improving commercial execution.